GLP1R and chronic kidney disease: Secondary analyses of these trials provided preliminary evidence also supporting a kidney protective effect of GLP-1 receptor agonists that remains to be demonstrated by the ongoing FLOW study, a phase 3 trial designed to test the safety and efficacy of semaglutide specifically in patients with T2DM and CKD.